These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10906412)

  • 21. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.
    Bromidge SM; Brown AM; Clarke SE; Dodgson K; Gager T; Grassam HL; Jeffrey PM; Joiner GF; King FD; Middlemiss DN; Moss SF; Newman H; Riley G; Routledge C; Wyman P
    J Med Chem; 1999 Jan; 42(2):202-5. PubMed ID: 9925723
    [No Abstract]   [Full Text] [Related]  

  • 22. Oxindole derivatives as orally active potent growth hormone secretagogues.
    Tokunaga T; Hume WE; Umezome T; Okazaki K; Ueki Y; Kumagai K; Hourai S; Nagamine J; Seki H; Taiji M; Noguchi H; Nagata R
    J Med Chem; 2001 Dec; 44(26):4641-9. PubMed ID: 11741481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
    Wan Y; Wallinder C; Plouffe B; Beaudry H; Mahalingam AK; Wu X; Johansson B; Holm M; Botoros M; Karlén A; Pettersson A; Nyberg F; Fändriks L; Gallo-Payet N; Hallberg A; Alterman M
    J Med Chem; 2004 Nov; 47(24):5995-6008. PubMed ID: 15537354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
    Egbertson MS; Cook JJ; Bednar B; Prugh JD; Bednar RA; Gaul SL; Gould RJ; Hartman GD; Homnick CF; Holahan MA; Libby LA; Lynch JJ; Lynch RJ; Sitko GR; Stranieri MT; Vassallo LM
    J Med Chem; 1999 Jul; 42(13):2409-21. PubMed ID: 10395482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiazole-derived potent, highly bioavailable short duration growth hormone secretagogues.
    Yang L; Morriello G; Leung K; Jacks T; Cheng K; Schleim KD; Smith R; Patchett AA
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1761-6. PubMed ID: 10406638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ipamorelin, the first selective growth hormone secretagogue.
    Raun K; Hansen BS; Johansen NL; Thøgersen H; Madsen K; Ankersen M; Andersen PH
    Eur J Endocrinol; 1998 Nov; 139(5):552-61. PubMed ID: 9849822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.
    Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G
    Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.
    Pan LC; Carpino PA; Lefker BA; Ragan JA; Toler SM; Pettersen JC; Nettleton DO; Ng O; Pirie CM; Chidsey-Frink K; Lu B; Nickerson DF; Tess DA; Mullins MA; MacLean DB; DaSilva-Jardine PA; Thompson DD
    Endocrine; 2001 Feb; 14(1):121-32. PubMed ID: 11322494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
    Svensson J; Monson JP; Vetter T; Hansen TK; Savine R; Kann P; Bex M; Reincke M; Hagen C; Beckers A; Ilondo MM; Zdravkovic M; Bengtsson BA; Korbonits M;
    Clin Endocrinol (Oxf); 2003 May; 58(5):572-80. PubMed ID: 12699438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors.
    Coburn CA; Rush DM; Williams PD; Homnick C; Lyle EA; Lewis SD; Lucas BJ; Di Muzio-Mower JM; Juliano M; Krueger JA; Vastag K; Chen IW; Vacca JP
    Bioorg Med Chem Lett; 2000 May; 10(10):1069-72. PubMed ID: 10843219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues.
    Huang P; Loew GH; Funamizu H; Mimura M; Ishiyama N; Hayashida M; Okuno T; Shimada O; Okuyama A; Ikegami S; Nakano J; Inoguchi K
    J Med Chem; 2001 Nov; 44(24):4082-91. PubMed ID: 11708912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New renin inhibitors containing pseudodipeptidic units in P3-P2 and P1-P1' positions.
    Paruszewski R; Jaworski P; Bodnar M; Dudkiewicz-Wilczyńska J; Roman I
    Chem Pharm Bull (Tokyo); 2005 Oct; 53(10):1305-9. PubMed ID: 16204988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.
    Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS
    Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK(2) receptor antagonists.
    Gensini M; Altamura M; Dimoulas T; Fedi V; Giannotti D; Giuliani S; Guidi A; Harmat NJ; Meini S; Nannicini R; Pasqui F; Tramontana M; Triolo A; Maggi CA
    ChemMedChem; 2010 Jan; 5(1):65-78. PubMed ID: 19957262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors.
    Wu C; Decker ER; Blok N; Bui H; Chen Q; Raju B; Bourgoyne AR; Knowles V; Biediger RJ; Market RV; Lin S; Dupré B; Kogan TP; Holland GW; Brock TA; Dixon RA
    J Med Chem; 1999 Nov; 42(22):4485-99. PubMed ID: 10579813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers.
    Agersø H; Ynddal L; Søgaard B; Zdravkovic M
    J Clin Pharmacol; 2001 Feb; 41(2):163-9. PubMed ID: 11210396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Super-active analogs of growth hormone-releasing factor (1-29)-amide.
    Lance VA; Murphy WA; Sueiras-Diaz J; Coy DH
    Biochem Biophys Res Commun; 1984 Feb; 119(1):265-72. PubMed ID: 6231028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
    Das J; Kimball SD; Hall SE; Han WC; Iwanowicz E; Lin J; Moquin RV; Reid JA; Sack JS; Malley MF; Chang CY; Chong S; Wang-Iverson DB; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML
    Bioorg Med Chem Lett; 2002 Jan; 12(1):45-9. PubMed ID: 11738570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New active series of growth hormone secretagogues.
    Guerlavais V; Boeglin D; Mousseaux D; Oiry C; Heitz A; Deghenghi R; Locatelli V; Torsello A; Ghé C; Catapano F; Muccioli G; Galleyrand JC; Fehrentz JA; Martinez J
    J Med Chem; 2003 Mar; 46(7):1191-203. PubMed ID: 12646029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.